drugset / Trial / NCT05144841
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Timeline
- Start
- 2022-01-08
- Primary completion
- 2026-04-21
- Completion
- 2026-04-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zilovertamab vedotin | Unknown | 2.25 mg/kg | Intravenous |
| Subject | Zilovertamab vedotin | Unknown | 2.5 mg/kg | Intravenous |